Literature DB >> 12100494

Progressive appearance of pigmentation in amelanotic melanoma lesions.

Karine A Cohen-Solal1, Steven M Crespo-Carbone, Jin Namkoong, Kerine R Mackason, Kathleen G Roberts, Kenneth R Reuhl, Suzie Chen.   

Abstract

We previously described a transgenic mouse line (TG-3) that spontaneously develops pigmented cutaneous melanoma. The generation of several albino mice that developed amelanotic melanoma has also been reported. In this report, we describe an unanticipated result with crosses between C57BL/6-c2j and TG-3 mice. C57BL/6-c2j has the same genetic background as TG-3 (C57BL/6), except for a single base mutation (nucleotide 291) in the tyrosinase locus, resulting in albino coat colour. Only albino F2 mice generated from (TG-3 x C57BL/6-c2j) F1s were selected for further studies. Mice that contained the transgene showed a very high incidence of tumor development as early as 4-6 weeks of age. Raised amelanotic tumors developed on the ear pinnae and perianal region in young F2 albino mice, similar phenotypes as those described earlier for the other albino inbred strains. However, with time, these amelanotic tumors not only increased in size, but unexpectedly developed foci of dark pigmentation. DNA sequence analysis on reverse transcriptase-polymerase chain reactions (RT-PCRs) of tyrosinase mRNA showed that the original tyrosinase mutation was still present in the tumors, indicating that no reversion at this nucleotide had occurred in the tumors. Two different tyrosinase activity assays were used and tyrosinase activity was detected in most tumor samples. Furthermore, Western blot analysis demonstrated various levels of tyrosinase protein in ear tumor samples. These results suggest that tyrosinase and/or melanin are not directly involved in the establishment of melanoma, but that late events occurring within the tumors may generate some tyrosinase activity and production of melanin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100494     DOI: 10.1034/j.1600-0749.2002.02024.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  12 in total

1.  The Tyr (albino) locus of the laboratory mouse.

Authors:  Friedrich Beermann; Seth J Orlow; M Lynn Lamoreux
Journal:  Mamm Genome       Date:  2004-10       Impact factor: 2.957

2.  Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.

Authors:  Brian A Wall; Janet Wangari-Talbot; Seung S Shin; Devora Schiff; Jairo Sierra; Lumeng J Yu; Atif Khan; Bruce Haffty; James S Goydos; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2014-01-22       Impact factor: 4.693

3.  Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.

Authors:  Jessica L F Teh; Raj Shah; Stephanie La Cava; Sonia C Dolfi; Madhura S Mehta; Sameera Kongara; Sandy Price; Shridar Ganesan; Kenneth R Reuhl; Kim M Hirshfield; Vassiliki Karantza; Suzie Chen
Journal:  Breast Cancer Res Treat       Date:  2015-04-10       Impact factor: 4.872

4.  Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma.

Authors:  Raj Shah; Simar J Singh; Fabian V Filipp; Suzie Chen; Kevinn Eddy
Journal:  Cancer Res       Date:  2019-04-15       Impact factor: 12.701

5.  In vitro and in vivo evaluation of melanin-binding decapeptide 4B4 radiolabeled with 177Lu, 166Ho, and 153Sm radiolanthanides for the purpose of targeted radionuclide therapy of melanoma.

Authors:  Beau Ballard; Zewei Jiang; Clifford E Soll; Ekaterina Revskaya; Cathy S Cutler; Ekaterina Dadachova; Lynn C Francesconi
Journal:  Cancer Biother Radiopharm       Date:  2011-10-04       Impact factor: 3.099

6.  Oxidative stress level and tyrosinase activity in vitiligo patients.

Authors:  M Eskandani; J Golchai; N Pirooznia; S Hasannia
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

7.  AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1).

Authors:  Seung-Shick Shin; Brian A Wall; James S Goydos; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-20       Impact factor: 4.693

8.  Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation.

Authors:  Seung-Shick Shin; Jin Namkoong; Brian A Wall; Ryan Gleason; Hwa Jin Lee; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2008-04-23       Impact factor: 4.693

9.  Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.

Authors:  Jessica L F Teh; Raj Shah; Seung-Shick Shin; Yu Wen; Janice M Mehnert; James Goydos; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2014-04-11       Impact factor: 4.693

10.  Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma.

Authors:  M Klein; M Lotem; T Peretz; S T Zwas; S Mizrachi; Y Liberman; R Chisin; J Schachter; I G Ron; G Iosilevsky; J A Kennedy; E Revskaya; A W de Kater; E Banaga; V Klutzaritz; N Friedmann; E Galun; G L Denardo; S J Denardo; A Casadevall; E Dadachova; G B Thornton
Journal:  J Skin Cancer       Date:  2013-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.